Article ID Journal Published Year Pages File Type
3369779 Journal of Clinical Virology 2009 5 Pages PDF
Abstract
In patients with pretreatment HBV-DNA levels ≤108 copies/mL, lamivudine could be withdrawn after achieving effective maintained virological suppression. Relapse of HBeAg-negative hepatitis remained a major problem.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Preview
Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression
Authors
, , , ,